21 Apr, 2026 By Rishabh Kale
Emami Bets Big on Functional Beverages with AloFrut

Emami is strategically expanding into the high-growth functional beverages segment through its investment in Axiom Ayurveda, the maker of AloFrut. This move is not merely exploratory but represents a calculated attempt to build a scalable brand in a rapidly expanding category. The functional beverages market is currently valued between $3.7 billion and $6.5 billion and is growing at an estimated rate of 11%, making it one of the most attractive adjacencies for FMCG companies.

Emami had earlier acquired a minority stake in Axiom Ayurveda in 2023, and AloFrut had already established a presence in southern markets with strong brand ambassadors and a revenue of ₹250 crore in FY24. However, the brand saw a decline in FY25 revenues to ₹107 crore, though it is expected to recover and reach ₹180 crore by FY27. The company now aims to scale AloFrut into a ₹400–500 crore brand within the next four to five years by leveraging its distribution network, expanding into new markets, and strengthening its positioning in the beverages category.

The company acknowledges that the move is challenging due to the highly competitive and consolidated nature of the beverages market compared to personal care. It faces strong competition from established brands such as Dabur’s Real juices, PepsiCo’s Tropicana, Paper Boat, and multiple D2C players.

Conclusion:
This news is structurally positive for Emami, as it signals diversification into a high-growth category with long-term potential. However, execution risk remains high due to intense competition and lower margins.

NIFTY – ₹24,353
NIFTY FMCG – ₹49,658
Emami – ₹454

21 Apr, 2026 By Rishabh Kale
FMCG Stocks Lose Investor Appeal as Valuations Hit Multi-Year Lows

The fast-moving consumer goods (FMCG) sector is witnessing a clear loss of investor interest, with valuations correcting sharply to a six-year low. The trailing price-to-earnings (P/E) ratio of FMCG companies within the NSE index has declined to 38.8X, significantly down from 43.9X at the end of March last year. This marks the lowest level since the January–March 2020 quarter, when valuations had fallen to 37.3X during the pandemic-induced lockdown. The sharp correction reflects a structural shift in investor sentiment away from defensive consumption stocks.

In contrast, broader market valuations have remained relatively stable. The Sensex is currently trading at a trailing P/E of 21.55X, only marginally lower than 21.58X at the end of March 2025. Compared to the pandemic period, when Sensex valuations had dropped to 19.6X in March 2020, the current stability indicates that the valuation compression is largely specific to FMCG stocks rather than a broader market correction.

This divergence has led to a significant decline in the premium that FMCG stocks command over the benchmark index. Currently, FMCG stocks trade at an 80% premium to the Sensex, down sharply from 103.4% a year ago. The narrowing premium indicates that investors are reassessing growth prospects in the sector amid concerns around demand moderation, margin pressures, and lack of strong earnings triggers.

Conclusion:
This development is negative for FMCG stocks in the near term, particularly for companies like Hindustan Unilever, Nestlé India, Dabur, and Britannia, as valuation compression can limit upside despite stable earnings. Investors should avoid aggressive fresh buying and wait for clearer demand recovery or margin expansion triggers, while long-term investors may consider gradual accumulation at lower valuation levels.